MedTrace Logo

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

NCT05557877 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-12

No results posted yet for this study

Summary

This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may affect markers of inflammation in blood and tissue and may prevent postpartum related breast cancer.

Conditions

  • Breast Carcinoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood

DRUG

Low-Dose Aspirin

Given PO

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Biopsy

Undergo breast biopsy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Kathryn J. Ruddy, MD · Mayo Clinic in Rochester

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-09
Primary Completion
2027-01-30
Completion
2027-01-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05557877 on ClinicalTrials.gov